Adipose stem cell therapy - Anterogen

Drug Profile

Adipose stem cell therapy - Anterogen

Alternative Names: Allogeneic mesenchymal stem cells - Anterogen; Adipocell (Anterogen); AdipoPlus; Adipose-derived stem cells; ALLO-ASC; ALLO-ASC-DFU; ALLO-ASC-EB; ALLO-ASC-OA; ALLO-ASC-TI; Allogeneic adipose stem cells; ANTG-ASC; Autologous adipose stem cells; Cupistem; Queencell

Latest Information Update: 14 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Anterogen
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Rectal fistula
  • New Molecular Entity No

Highest Development Phases

  • Marketed Rectal fistula; Scars; Subcutaneous fat disorders
  • Phase II Diabetic foot ulcer
  • Phase I/II Tendon injuries
  • Phase I Burns; Crohn's disease; Epidermolysis bullosa
  • Preclinical Chronic wounds; IgA nephropathy; Osteoarthritis

Most Recent Events

  • 21 Nov 2016 Anterogen terminates a phase-II clinical trial in Rectal fistula in South Korea prior to November 2016 (NCT01314092) (Injection)
  • 07 Dec 2015 Anterogen plans a phase II trial for Burns in South Korea (NCT02619851)
  • 01 Oct 2015 Phase-II clinical trials in Diabetic foot ulcer in South Korea (NCT02619877)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top